Manipulation of immunity to and pathology of respiratory infections

References

• Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 34,1436–1442 (1997).
   Google Scholar
• ••Comprehensive overview illustrating theglobal impact of respiratory infections.
   Google Scholar
• Gwaltney JM. Viral respiratory infection therapy: historical perspectives and current trials. Am. J. Med. 11(Suppl. 6A), S33-S41 (2002).
   Google Scholar
• Yamaya M, Sasaki H. Rhinovirus and asthma. Viral Immunol 1, 99–109 (2003).
   Google Scholar
• Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 2, 3068–3087 (2002).
   Google Scholar
• McNamara PS, Smyth RL. The pathogenesis of respiratory syncytial virus disease in childhood. Br. Med Bull. 6, 13–28 (2002).
   Google Scholar
• Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir. Rev. 5\(Suppl. 1), S119-S126 (2004).
   PubMedGoogle Scholar
• Cox NJ, Subbarao K Influenza. Lancet 35, 1277–1282 (1999).
   Google Scholar
• Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia etiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 5,296–301 (2001).
   Google Scholar
• Engelich G, White M, Hartshorn KL. Neutrophil survival is markedly reduced by incubation with influenza virus and Streptococcus pneumoniae: role of respiratory burst. J. Leukoc. Bid 6,50–56 (2001).
   Google Scholar
• Harrison TS Gyptococcus neofonnans and cryptococcosis •Demonstrates how one respiratory pathogen can alter the outcome of infection of another. Multiple infections are common and it is often the combination that leads to serious disease. to.. J. Infect. 4,12–17 (2000).
   Google Scholar
• Rodrigues ML, Alviano CS, Travassos LR Pathogenicity of Cryptococcus neoformans: virulence factors and immunological mechanisms. Microbes Infia. 1(4), 293–301 (1999).
   Google Scholar
• •Underlying immune deficiencies reduce the ability to contain respiratory pathogens. In the case of Gypococcus neoformans this can result in fungal meningitis.
   Google Scholar
• Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin. Microbial Rev. 1, 637–646 (2003).
   Google Scholar
• Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. J. Clin. Invest 10,693–697 (2002).
   Google Scholar
• Boyton RJ, Openshaw PJ. Pulmonary defences to acute respiratory infection. Br. Med. Bull. 6,1–12 (2002).
   Google Scholar
• Farnaud S, Evans RW. Lactoferrin-a multifunctional protein with antimicrobial properties. Mal. Immunal 4,395–405 (2003).
   Google Scholar
• Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobial peptides, such as defensins in innate and adaptive immunity. Ann. Rheum. Dis. 62\(Suppl. 2), ii17-ii21 (2003).
   PubMedGoogle Scholar
• Holmskov U, Thiel S, Jensenius JC. Collections and ficolins: humoral lectins of the innate immune defence. Ann. Rev. Immunol 2,547–578 (2003).
   Google Scholar
• Gordon SB, Read RC. Macrophage defences against respiratory tract infections. Br. Med. Bull. 6,45–61 (2002).
   Google Scholar
• •Highlights how alveolar macrophages are central to immunological homeostasis in the lung.
   Google Scholar
• Wang SZ, Forsyth KD. The interaction of neutrophils with respiratory epithelial cells in viral infection. Respirology 5(1), 1–10 (2000).
   PubMedGoogle Scholar
• Hayday A, Viney JL. The ins and outs of body surface immunology. Science 29, 97–100 (2000).
   Google Scholar
• •Provides an overview of the mucosal immune system. The majority of the data regard the gastrointestinal tract. However, certain features are also present in the lung, especially intraepithelial lymphocytes.
   Google Scholar
• Lamm ME. Current concepts in mucosal immunity. IV. How epithelial transport of IgA antibodies relates to host defence. Am. J. Physiol. 27, G614–G617 (1998).
   Google Scholar
• Julkunen I, Sareneva T, Pirhonen J, Ronni T, Melen K, Matikainen S. Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev. 1, 171–180 (2001).
   Google Scholar
• McIntosh K, Fishaut JM. Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus. Prog. Med. Viral. 2,94–118(1980).
   Google Scholar
• Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemial 8,449–463 (1969).
   Google Scholar
• ••One of the earliest examples of a vaccination regimen that enhanced disease due to immune augmentation.
   Google Scholar
• Hussell T, Pennycook A, Openshaw PJM. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur. J. Immunol 31, 2566–2573 (2001).
   PubMed Web of Science ®Google Scholar
• Peper RL, Van Campen H. Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia. Microb. Pathog. 1,175–183 (1995).
   Google Scholar
• Kurokawa M, Imakita M, Kumeda CA, Shiraki K. Cascade of fever production in mice infected with influenza virus. J. Med. Viral. 5,152–158 (1996).
   Google Scholar
• Kozak W, Conn CA, Klir JJ, Wong GH, Kluger MJ. TNF soluble receptor and antiserum against TNF enhance lipopolysaccharide fever in mice. Am. J. Physiol. 26, R23–R29 (1995).
   Google Scholar
• Kozak W, Poli V, Soszynski D, Conn CA, Leon LR, Kluger MJ. Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am. J. Physiol. 27, R621–R630 (1997).
   Google Scholar
• Cook DN. The role of MIP-lot in inflammation and hematopoiesis.J. Leukoc. Biol. 5,61–66 (1996).
   Google Scholar
• Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin-8 gene region in UK families. Thorax 5, 1023–1027 (2000).
   Google Scholar
• •Excellent example of how polymorphisms in a gene encoding a proinflammatory cytokine correlate with disease severity.
   Google Scholar
• Becker S, Soukup JM. Airway epithelial cell-induced activation of monocytes and eosinophils in respiratory syncytial viral infection. Immunobiology 20,88–106 (1999).
   Google Scholar
• Panuska JR, Merolla R, Rebert NA, et al. Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages-suppression of early cytokine production and implications for incomplete immunity. J. Clin. Invest. 9, 2445–2453 (1995).
   Google Scholar
• Suliman HB, Ryan LK, Bishop L, Folz RJ. Prevention of influenza-induced lung injury in mice overexpressing extracellular superoxide dismutase. Am. J. Physiol Lung Cell. Mal. Physiol 28, L69–L78 (2001).
   Google Scholar
• Akaike T. Role of free radicals in viral pathogenesis and mutation. Rev. Med. Viral. 1, 87–101 (2001).
   Google Scholar
• Small BA, Dressel SA, Lawrence CW, et al. CD8(+) T-cell-mediated injury in vivo progresses in the absence of effector T-cells. J. Exp. Med 19,1835–1846 (2001).
   Google Scholar
• Wiley JA, Cerwenka A, Harkema JR, Dutton RW, Harmsen AG. Production of interferon-y by influenza hemagglutinin-specific CD8 effector T-cells influences the development of pulmonary immunopathology. Am. J. Pathol 15, 119–130 (2001).
   Google Scholar
• Graham BS, Bunton LA, Wright PF, Karzon DT Role of T-lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest. 8,1026–1033 (1991).
   Google Scholar
• ••Highlights how T-cell depletion reducespathology in respiratory syncytial virus (RSV)-infected mice despite prolonged virus presence.
   Google Scholar
• Ostler T, Davidson W EM S. Virus clearance and immunopathology by CD8(+) T-cells during infection with respiratory syncytial virus are mediated by IFN-y. Eur.J. Immunol 3,2117–2123 (2002).
   Google Scholar
• Alwan WH, Kozlowska WJ, Openshaw PJM. Distinct types of lung disease caused by functional subsets of antiviral T-cells. J. Exp. Med 17, 81–89 (1994).
   Google Scholar
• ••One of the earliest studies showing that theoutcome of RSV infection is determined by the type of T-cell that is induced.
   Google Scholar
• Boelen A, Kwakkel J, Barends M, de Rond L, Dormans J, Kimman T Effect of lack of interleukin-4, interleukin-12, interleukin-18, or the interferon-y receptor on virus replication, cytokine response and lung pathology during respiratory syncytial virus infection in mice. J. Med. Viral 6,552–560 (2002).
   Google Scholar
• Renzi PM, Turgeon JP, Marcotte JE, et al. Reduced interferon-y production in infants with bronchiolitis and asthma. Am. J. Respir. Crit. Care Med. 15,1417–1422 (1999).
   Google Scholar
• Roman M, Calhoun WJ, Hinton KL, et al. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am. J. Respir. Crit. Care Med. 15,190–195 (1997).
   Google Scholar
• Renzi PM, Turgeon JP, Yang JP, et al. Cellular immunity is activated and a Th-2 response is associated with early wheezing in infants after bronchiolitis. J. Pediatr. 13, 584–593 (1997).
   Google Scholar
• Berry AM, Alexander JE, Mitchell TJ, Andrew PW, Hansman D, Paton JC. Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae. Infect. Immun. 6, 1969–1974 (1995).
   Google Scholar
• Canvin JR, Marvin AP, Sivakumaran M, et al. The role of pneumolysin and autolysin in the pathology of pneumonia and septicemia in mice infected with a Type 2 pneumococcus. J. Infect. Dis. 17, 119–123 (1995).
   Google Scholar
• Paton JC, Andrew PW, Boulnois GJ, Mitchell TJ. Molecular analysis of the pathogenicity of Streptococcus pneumoni ae: the role of pneumococcal proteins. Ann. Rev. Microbial 4,89–115 (1993).
   Google Scholar
• Blue CE, Paterson GK, Kerr AR, Berge M, Claverys JP, Mitchell TJ. ZmpB, a novel virulence factor of Streptococcus pneumoniae that induces tumor necrosis factor-a production in the respiratory tract. Infect. Immun. 7, 4925–4935 (2003).
   Google Scholar
• Fenton MJ, Vermeulen MW Immunopathology of tuberculosis: roles of macrophages and monocytes. Infect. Immun. 6,683–690 (1996).
   Google Scholar
• Kyd JM, Foxwell AR, Cripps AW. Mucosal immunity in the lung and upper airway. Vaccine 1, 2527–2533 (2001).
   Google Scholar
• •Provides an overview of immunity in the respiratory tract.
   Google Scholar
• Poland GA, Rottinghaus ST, Jacobson RM. Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine 1, 2216–2220 (2001).
   Google Scholar
• Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 36, 1733–1745 (2003).
   Google Scholar
• Hilleman MR. Serologic responses to split and whole swine influenza virus vaccines in light of the next influenza pandemic. J. Infect. Dis. 136(Suppl.), S683-S685 (1977).
   PubMedGoogle Scholar
• Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur. Respir. J. 1,1282–1293 (2001).
   Google Scholar
• Kendal AE Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Eur. Epidemiol. 1,591–609(1997).
   Google Scholar
• Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J. Med. 33,1405–1412 (1998).
   Google Scholar
• Donnelly JJ, Ulmer JB, Shiver JXT, Liu MA. DNA vaccines. Ann. Rev. Immunol 1,617–648 (1997).
   Google Scholar
• Ulmer JB, Donnelly JJ, Parker, et al Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 25,1745–1749 (1993).
   Google Scholar
• Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature Med. 5(10), 1157–1163 (1999).
   PubMed Web of Science ®Google Scholar
• Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J. Med. 33,874–880 (1997).
   Google Scholar
• Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 35,1845–1850 (2000).
   Google Scholar
• Bachmann MF, Kopf M. Balancing protective immunity and immunopathology. Curr. Opin. Immunol 1, 413–419 (2002).
   Google Scholar
• ••Highlights the equilibrium required forthe immune system to fight infection without causing excessive collateral damage. Directly complements this article.
   Google Scholar
• Wilkinson KA, Martin TD, Reba SM, et al. Latency-associated peptide of transforming growth factor-13 enhances mycobacteriocidal immunity in the lung during Mycobacterium bovis BCG infection in C57BL/6 mice. Infect. Immun. 6, 6505–6508 (2000).
   Google Scholar
• Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K. Role of tumor necrosis factor-a in pathogenesis of pneumococcal pneumonia in mice. Infect. Immun. 6,257–260 (1997).
   Google Scholar
• •Makes the important point that although inflammatory cytoldnes cause pathology, their depletion can cause death due to increased pathogen load.
   Google Scholar
• Nauciel C, Espinasse-Maes F. Role of y-interferon and tumor necrosis factor-a in resistance to Salmonella ophimurium infection. Infect. Immun. 6,450–454 (1992).
   Google Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-a neutralizing agent. N Engl J. Med. 34,1098–1104 (2001).
   Google Scholar
• •Depletion of inflammatory cytolcines can lead to death due to enhanced pathogen replication.
   Google Scholar
• Hart PH, Ahern MJ, Smith MD, Finlay-Jones JJ. Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis. Immunology 8, 536–542 (1995).
   Google Scholar
• Hart PH, Jones CA, Finlay-Jones JJ. Monocytes cultured in cytokine-defined environments differ from freshly isolated monocytes in their responses to IL-4 and IL-10. J. Leukoc. Biol. 5,909–918 (1995).
   Google Scholar
• Morrison DF, Foss DL, Murtaugh MR Interleukin-10 gene therapy-mediated amelioration of bacterial pneumonia. Infect. Immun. 6,4752–4758 (2000).
   Google Scholar
• Sawa T, Corry DB, Gropper MA, Ohara M, Kurahashi K, Wiener-Kronish JP. IL-10 improves lung injury and survival in Pseudo monas aeruginosa pneumonia. J. Immunol. 15,2858–2866 (1997).
   Google Scholar
• Standiford TJ, Wilkowski JM, Sisson TH, et al. Intrapulmonary tumor necrosis factor gene therapy increases bacterial clearance and survival in murine Gram-negative pneumonia. Hum. Gene Then 1, 899–909 (1999).
   Google Scholar
• van Der PT, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J. Infect. Dis. 17, 994–1000 (1996).
   Google Scholar
• Kunkel SL, Lukacs NW, Strieter RI\4, Chensue SW. The role of chemokines in the immunopathology of pulmonary disease. Forum (Genova.) 9(4), 339–355 (1999).
   PubMedGoogle Scholar
• Tamaoki J. The effects of macrolides on inflammatory cells. Chest 12, S41–S50 (2004).
   Google Scholar
• Humphreys IR, Walzl G, Edwards L, Rae A, Hill S, Hussell T. A critical role for 0X40 in T-cell-mediated immunopathology during lung viral infection. J. Exp. Med. 19,1237–1242 (2003).
   Google Scholar
• •Highlights a novel strategy that dampens only antigen-specific T-cells, which alleviates pathology during influenza infection.
   Google Scholar
• Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of Type 1 T-helper cells (This) and Th2s. J. Exp. Med. 18,129–134 (1998).
   Google Scholar
• Loetscher P, Uguccioni M, Bordoli L, et al. CCR5 is characteristic of Thl lymphocytes (letter). Nature 39,344–345 (1998).
   Google Scholar
• Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on Type 2 but not Type 1 helper T-cells. J. Exp. Med. 18,787–794 (1998).
   Google Scholar
• Ho IC, Hodge MR, Rooney JV,/, Glimcher LH. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 8,973–983 (1996).
   Google Scholar
• Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T-cells. Cell 8,587–596 (1997).
   Google Scholar
• Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T-helper 1 and 2 lymphocytes. J. Exp. Med. 18,875–883 (1998).
   Google Scholar
• Walzl G, Matthews S, Kendall S, et al. Inhibition of Tl/ST2 during respiratory syncytial virus infection prevents T-helper cell Type 2 (Th2)-but not Thl-driven immunopathology. J. Exp. Med. 19, 785–792 (2001).
   Google Scholar
• Varga SM, Wang X, Welsh RIVI, Braciale TJ. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T-cells. Immunity 1, 637–646 (2001).
   Google Scholar
• Humphreys IR, Edwards L, Walzl G, et al. 0X40 ligation on activated T-cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. Immunol. 17, 6125–6132 (2003).
   Google Scholar